Page last updated: 2024-11-05

2-methylbutanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Methylbutanoic acid, also known as iso-valeric acid, is a branched-chain fatty acid with a pungent odor. It occurs naturally in some plants and animals and is a common component of cheese and other fermented foods. 2-Methylbutanoic acid is synthesized through various methods, including the oxidation of isovaleraldehyde and the hydrolysis of isovaleryl chloride. It is also produced by microbial fermentation. 2-Methylbutanoic acid is studied for its potential biological activities. It has been found to have antibacterial, antifungal, and anti-inflammatory properties. It is also believed to play a role in the development of certain diseases, such as diabetes and Alzheimer's disease. 2-Methylbutanoic acid is used in the production of pharmaceuticals, food additives, and fragrances. It is also used as a solvent and a flavoring agent.'

2-methylbutanoic acid: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-methylbutyric acid : A methylbutyric acid comprising a butyric acid core carrying a 2-methyl substituent. Produced from amino acid leucine during nutrient starvation in bacteria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8314
CHEMBL ID1160012
CHEBI ID37070
SCHEMBL ID49960
MeSH IDM0071945

Synonyms (108)

Synonym
carbomer 934
carbopol 934
2-methyl-butyric acid
2-methylbutyric acid
butyric acid, 2-methyl-
nsc-7304
butanoic acid, 2-methyl-
nsc7304
active valeric acid
.alpha.-methylbutyric acid
2-methybutyric acid
ethylmethylacetic acid
116-53-0
methylethylacetic acid
2-methylbutanoic acid
butanoic acid, 2-methyl-, (+ -)
smr000112113
MLS001055480
2-methylbutyric acid (van)
fema no. 2695
valeric acid, active
2-methylbutyric acid (natrual)
einecs 204-145-2
(1)-2-methylbutyric acid
ai3-24202
einecs 209-982-7
nsc 7304
brn 1098537
2-methyl butyric acid
carbopol 974p
butane-2-carboxylic acid
alpha-methylbutyric acid
CHEBI:37070 ,
600-07-7
NCGC00090971-01
(+/-)-2-methylbutyric acid, natural, >=98%, fg
2-methylbutyric acid, >=98%, fg
2-methyl-butanoic acid
LMFA01020072
alpha-methyl butyric acid
2-methylbutyric acid, 98%
C18319
M0181
dl-2-methylbutyric acid
2-methyl-butyric acid anion
CHEMBL1160012
AKOS000121120
NCGC00090971-02
NCGC00257513-01
tox21_303584
dtxsid5021621 ,
cas-116-53-0
dtxcid301621
tox21_201807
NCGC00259356-01
rac-2-methylbutanoic acid
(rs)-2-methyl-butyric acid
HMS2270O06
carbomer 934 [usan:nf]
9007-16-3
AM802977
FT-0671578
FT-0671579
unii-px7znn5gxk
ec 204-145-2
px7znn5gxk ,
2-methylbutanoic acid (dl)
4-02-00-00889 (beilstein handbook reference)
FT-0608333
FT-0605255
FT-0604458
(+/-)-2-methylbutyric acid
SCHEMBL49960
dl-.alpha.-methylbutyric acid
2-methylbutyric acid [fhfi]
2-methylbutyric acid, dl-
2-methylbutyric acid [fcc]
AKOS016843247
(.+/-.)-2-methylbutanoic acid
methylbutyricacid
mfcd00002669
F0001-0289
butanoic acid, methyl-
J-509893
CS-W001942
2-methylbutyric acid, analytical standard
ethylmethylacetate
(+/-)-2-methylbutyrate
d-2-methyl butyric acid
dl-2-methy butyric acid
dl-2-methy butyrate
2-ethylpropionate
d-2-methyl butyrate
dl-2-methylbutyrate
2-ethylpropionic acid
2-methyl butyrate
Q209433
dl-2-methylbutyricacid
d-2-methylbutyricacid
2-methylbutyricacid
SB47880
2-methylbutanoicacid
SY115833
EN300-27063
PD041098
(s)-(+)-2-methylbutyricacid-d3
dl-2-methyl-d3-butyricacid
Z237374874
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
methylbutyric acidA methyl-branched fatty acid comprising a butyric acid core carrying a single methyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency65.32210.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency7.31710.000221.22318,912.5098AID1259247
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency32.68440.003041.611522,387.1992AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.85610.000229.305416,493.5996AID1259248
Histone H2A.xCricetulus griseus (Chinese hamster)Potency0.31850.039147.5451146.8240AID1224845
TAR DNA-binding protein 43Homo sapiens (human)Potency2.23871.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 20Mus musculus (house mouse)Ki40.71901.10006.67899.1201AID360149
Solute carrier family 22 member 6Mus musculus (house mouse)Ki916.00550.40745.02179.4000AID360150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID1750492Reduction of propionyl-CoA in human hepatocytes derived from propionic acidemia patient pretreated for 30 mins followed by 13C-isoleucine addition and measured after 1 hr by MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID1750491Reduction of propionyl-CoA in human hepatocytes derived from propionic acidemia patient at 100 uM pretreated for 30 mins followed by 13C-isoleucine addition and measured after 1 hr by MS/MS analysis relative to control2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
AID95754Protein interaction energy by using binding affinity towards human L-xylulose reductase enzyme2003Bioorganic & medicinal chemistry letters, Apr-17, Volume: 13, Issue:8
Structure-based design of inhibitors of human L-xylulose reductase modelled into the active site of the enzyme.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (94)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (23.40)18.7374
1990's7 (7.45)18.2507
2000's29 (30.85)29.6817
2010's28 (29.79)24.3611
2020's8 (8.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.68 (24.57)
Research Supply Index4.58 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index87.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.11%)5.53%
Reviews1 (1.05%)6.00%
Case Studies1 (1.05%)4.05%
Observational0 (0.00%)0.25%
Other91 (95.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]